EP
VIR icon

Essential Partners’s Vir Biotechnology VIR Stock Holding History

Essential Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.37K Sell
723
-307
-30% -$2.92K ﹤0.01% 1359
2026
Q1 		$9.23K Buy
1,030
+552
+115% +$4.4K ﹤0.01% 1298
2025
Q4 		$2.88K Buy
478
+10
+2% +$60 ﹤0.01% 1662
2025
Q3 		$2.67K Sell
468
-1,542
-77% -$7.88K ﹤0.01% 1696
2025
Q2 		$10.1K Buy
+2,010
New +$10.8K ﹤0.01% 839

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Essential Partners's VIR Position: Q2 2026 in Review

Essential Partners reduced its Vir Biotechnology (VIR) stake by 30% in Q2 2026, selling an estimated $2.92K and leaving 723 shares worth $7.37K. The position accounts for ﹤0.01% of the portfolio, ranked #1359.

Essential Partners first reported a position in VIR in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.1K in Q2 2025. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Essential Partners held 723 shares of Vir Biotechnology worth $7.37K as of Q2 2026.
  • Essential Partners sold 307 Vir Biotechnology shares in Q2 2026, an estimated $2.92K.
  • Vir Biotechnology made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1359 holding.
  • Essential Partners first reported a position in Vir Biotechnology in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Vir Biotechnology position peaked at $10.1K in Q2 2025.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.